U.S. Markets open in 46 mins

Pulse Biosciences, Inc. (PLSE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
13.25-0.25 (-1.85%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close13.50
Open13.49
Bid10.99 x 1200
Ask0.00 x 1000
Day's Range13.23 - 13.68
52 Week Range5.11 - 17.77
Volume29,333
Avg. Volume89,506
Market Cap334.059M
Beta (5Y Monthly)1.77
PE Ratio (TTM)N/A
EPS (TTM)-2.32
Earnings DateAug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
  • Business Wire

    Pulse Biosciences Announces Presentation of Clinical Results Using Nano-Pulse Stimulation Technology for the Clearance of Skin Lesions at the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting

    Pulse Biosciences, Inc. (Nasdaq: PLSE) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that clinical results from studies spanning the Company’s dermatologic application portfolio will be presented at the American Society for Dermatologic Surgery (ASDS) virtual annual meeting on October 9-11, 2020. Positive study results generated using the Company’s innovative cellular-specific Nano-Pulse Stimulation mechanism performed with its CellFX System for the treatment of sebaceous hyperplasia lesions, cutaneous non-genital warts, plantar warts, and basal cell carcinoma will be presented in two oral presentations and two e-posters.

  • Business Wire

    Pulse Biosciences Announces FDA IDE Approval and Initiation of Sebaceous Hyperplasia Study

    Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced FDA Investigational Device Exemption (IDE) approval and initiation of a pivotal study to evaluate the treatment of sebaceous hyperplasia (SH) lesions using the CellFX® System. The data generated from this study is intended to support a 510(k) submission to expand the indication for use of the CellFX System specifically to treat SH lesions.

  • Business Wire

    Pulse Biosciences Announces Receipt of MDSAP Certification

    Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced the receipt of Medical Device Single Audit Program certification.